cervicalcancerdyslipidemiacommunity-dwelling,postmenopausalwomen40y.o.diabeteshormonetherapybreastcancerraloxifenePREVENTequation3%q1-2ymammogrambased on lifeexpectancy /health status20%75y.o.anxietyhypertensionq3yq2y40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factorFractureRiskAssessmentToolwomenage 55-64 y.o.statin≥ 140mg/dLHIVovariancancerq2y52y.o.pneumococcal40-59 y.o.,ASCVD ≥10%, lowbleeding riskq15yaspirin50y.o.60y.o.≥ 200mg/dLq1ymammogramaromataseinhibitorsinsufficientevidenceforscreeningcardiovasculardiseaseq5y65y.o.Gailmodelq1yHepatitisB1 dose; 2doses (2-6monthsapart) ifimmunocomp< 60y.o.multidoseinitial series,then 1 doseat 2-6months40-70 y.o.,ASCVD ≥10%, lowbleeding risktobaccouse≥ 126mg/dL2 doses,2-6monthsapartdementiaTyrer-CuzickmodelTimedup andgo testlungcancerdepression40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsoverweight/ obesityherpeszosterHepatitisC≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors6.5%5.7%colorectalcancertamoxifen≥ 100mg/dL40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorcervicalcancerdyslipidemiacommunity-dwelling,postmenopausalwomen40y.o.diabeteshormonetherapybreastcancerraloxifenePREVENTequation3%q1-2ymammogrambased on lifeexpectancy /health status20%75y.o.anxietyhypertensionq3yq2y40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factorFractureRiskAssessmentToolwomenage 55-64 y.o.statin≥ 140mg/dLHIVovariancancerq2y52y.o.pneumococcal40-59 y.o.,ASCVD ≥10%, lowbleeding riskq15yaspirin50y.o.60y.o.≥ 200mg/dLq1ymammogramaromataseinhibitorsinsufficientevidenceforscreeningcardiovasculardiseaseq5y65y.o.Gailmodelq1yHepatitisB1 dose; 2doses (2-6monthsapart) ifimmunocomp< 60y.o.multidoseinitial series,then 1 doseat 2-6months40-70 y.o.,ASCVD ≥10%, lowbleeding risktobaccouse≥ 126mg/dL2 doses,2-6monthsapartdementiaTyrer-CuzickmodelTimedup andgo testlungcancerdepression40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsoverweight/ obesityherpeszosterHepatitisC≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors6.5%5.7%colorectalcancertamoxifen≥ 100mg/dL40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factor

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. cervical cancer
  2. dyslipidemia
  3. community-dwelling, postmenopausal women
  4. 40 y.o.
  5. diabetes
  6. hormone therapy
  7. breast cancer
  8. raloxifene
  9. PREVENT equation
  10. 3%
  11. q1-2y mammogram based on life expectancy / health status
  12. ≥ 20%
  13. 75 y.o.
  14. anxiety
  15. hypertension
  16. q3y
  17. ≤ q2y
  18. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  19. Fracture Risk Assessment Tool
  20. women age 55-64 y.o.
  21. statin
  22. ≥ 140 mg/dL
  23. HIV
  24. ovarian cancer
  25. q2y
  26. 52 y.o.
  27. pneumococcal
  28. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  29. q15y
  30. aspirin
  31. 50 y.o.
  32. 60 y.o.
  33. ≥ 200 mg/dL
  34. q1y mammogram
  35. aromatase inhibitors
  36. insufficient evidence for screening
  37. cardiovascular disease
  38. q5y
  39. 65 y.o.
  40. Gail model
  41. q1y
  42. Hepatitis B
  43. 1 dose; 2 doses (2-6 months apart) if immunocomp
  44. < 60 y.o.
  45. multidose initial series, then 1 dose at 2-6 months
  46. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  47. tobacco use
  48. ≥ 126 mg/dL
  49. 2 doses, 2-6 months apart
  50. dementia
  51. Tyrer-Cuzick model
  52. Timed up and go test
  53. lung cancer
  54. depression
  55. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  56. overweight / obesity
  57. herpes zoster
  58. Hepatitis C
  59. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  60. ≥ 6.5%
  61. ≥ 5.7%
  62. colorectal cancer
  63. tamoxifen
  64. ≥ 100 mg/dL
  65. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor